Drug intelligence / Profile preview

carboplatin + nab-paclitaxel + cobolimab + dostarlimab

Development stage: Unknown
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

**carboplatin + nab-paclitaxel + cobolimab + dostarlimab** is an investigational four-drug combination regimen used in oncology clinical trials. - **Carboplatin** is a platinum-based chemotherapy that induces DNA crosslinking and triggers apoptosis (programmed cell death) in rapidly dividing cells. - **Nab-paclitaxel** (albumin-bound paclitaxel) is a microtubule inhibitor chemotherapeutic formulated with albumin to improve delivery. - **Cobolimab** (anti-TIM-3 antibody) is an investigational monoclonal antibody targeting the immune checkpoint TIM-3, intended to enhance anti-tumor immunity by blocking inhibitory signals on T cells. - **Dostarlimab** (Jemperli) is a PD-1 receptor-blocking humanized monoclonal antibody immunotherapy that releases inhibitory brakes on immune cells for improved tumor cell recognition and destruction[3][6]. The combination is designed to maximize anti-tumor activity through complementary cytotoxic and immune checkpoint inhibition mechanisms. Typically explored for advanced or metastatic cancers including non-small-cell lung cancer and endometrial cancer; cobolimab is investigational.

Brand names: Abraxane (nab-paclitaxel)Jemperli (dostarlimab)
Other names: albumin-bound paclitaxel (for nab-paclitaxel)

Targets

PDCD1 (Programmed cell death protein 1 receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on carboplatin + nab-paclitaxel + cobolimab + dostarlimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + nab-paclitaxel + cobolimab + dostarlimab.

Explore the full profile